Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell Lymphoma

Video

Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.

Jonathan E. Brammer, MD,discusses data from the following poster: “Duvelisib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma From the Phase 2 PRIMO Trial: Results of an Interim Analysis” Brammer J, et al. ASH 2021, Abstract 2456).

Introduction

  • Relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) is a family of aggressive lymphomas, with a median overall survival (OS) of less than 6 months. Current FDA-approved therapies for R/R PTCL have modest overall response rates (ORRs) of < 30%.
  • In the phase 2, open-label, multicenter, parallel cohort PRIMO trial of duvelisib (a dual PI3K-δ,γ inhibitor) in R/R PTCL, the initial results of the dose-optimization phase (N=33) demonstrated a 54% ORR in the 75 mg twice a day (N=13) and 35% in the 25 mg twice a day (N=20) cohorts, respectively.
  • The objective of this presentation was to provide the interim results as of May 21, 2021, including the first 6 months of data for the 78 patients included in the analysis obtained from the PRIMO trial expansion phase.

Methods

  • PRIMO is a phase 2, open-label, multicenter, parallel cohort study of duvelisib in patients with R/R PTCL consisting of a dose optimization phase and an expansion phase (NCT03372057).
  • The expansion phase of PRIMO has a targeted enrollment of 125 patients. The expansion phase eligibility criteria included histologically confirmed R/R PTCL after >1 cycle of a prior standard regimen, a CD4 lymphocyte count of ≥ 50 per mm3 and required pneumocystis jiroveci prophylaxis.
  • Based on the dose optimization results, patients in the expansion phase receive duvelisib at 75 mg twice a day for 2 cycles to maximize rapid tumor control, followed by 25 mg twice a day to maintain long-term disease control and mitigate late toxicities, until progressive disease or unacceptable toxicity.
  • The primary end point is ORR by independent review committee assessment. Secondary end points include ORR by investigator assessment, duration of response (DOR), progression-free survival, OS, disease control rate, and safety. All analyses consisted of patients who received at least 1 dose of duvelisib.

Results

  • The interim results of the first 78 patients in the PRIMO expansion phase show an ORR of 50% and a CR rate of 32%.
  • Time to response was 53 days (range, 15 to 114 days), and median duration of response was 233 days (range, 1 to 420 days).
  • The most frequent grade ≥3 adverse events (AEs) were neutropenia, increased ALT/AST, rash, lymphocyte count decreased, and sepsis. Alanine aminotransferase and aspartate aminotransferase elevations were the most common AEs leading to treatment discontinuation.

Conclusion

  • Response rates with duvelisib suggest that this therapy is superior to available standard-of-care therapeutic options. These data build upon prior reports demonstrating duvelisib as an active oral treatment for patients with R/R PTCL.
  • Duvelisib was well tolerated in the given patient population and remained consistent with its known safety profile.
Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Guenther Koehne, MD, PhD
Lori A. Leslie, MD, an expert on lymphoma
Lori A. Leslie, MD, an expert on lymphoma
A panel of 4 experts on MDS
Elias Jabbour, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD